Abivax: four abstracts to be presented on obefazimod
These new preclinical data demonstrate the impact of obefazimod on tumor reduction in the azoxymethane/sodium salt dextran sulfate mouse model of inflammation-associated cancer," says Medical Director Sheldon Sloan.
Abstracts will be presented at Digestive Disease Week (DDW), May 18-21 in Washington, D.C., giving the biotech company the opportunity to continue its exchanges with the community of experts in this field.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction